Significance of Detection of CA153, CA125, and CA19-9 in Diagnosis of Breast Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

刘斌 , 孙国荣 , 王从俊 , 张辉 , 赵中辛

Corresponding author：

Keywords：

CA153; CA125; CA19-9; 乳腺癌

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的探讨血清CA153、CA125和CA19-9检测对乳腺癌早期诊断的价值。方法采用化学发光免疫法分别检测乳腺癌、乳腺良性疾病患者及正常健康体检者血清CA153、CA125和CA19-9的水平。结果乳腺癌患者血清的CA153、CA125和CA19-9的表达水平及表达阳性率均明显高于正常对照者和乳腺良性疾病患者(P lt;0.01)；乳腺癌患者术后CA153、CA125及CA19-9表达水平较术前明显下降(P lt;0.01)，与正常对照者比较差异无统计学意义(P gt;0.05)。结论肿瘤标志物CA153、CA125及CA19-9 对乳腺癌有一定的诊断价值，且可作为监测乳腺癌病情进展、评估治疗疗效及预后的指标。

Citation： 刘斌,孙国荣,王从俊,张辉,赵中辛. Significance of Detection of CA153, CA125, and CA19-9 in Diagnosis of Breast Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2011, 18(9): 991-992. doi: Copy

1.	张喜庆, 王珠, 乔新民. 乳腺癌的现状和远景 [J]. 中华外科杂志, 2002, 40(3): 161163.
2.	Haglund C, Lundin J, Kuusela P, et al. CA242, a new tumour marker for pancreatic cancer: a comparison with CA199, CA50 and CEA [J]. Br J Cancer, 1994, 70(3): 487492.
3.	Duffy MJ, Shering S, Sherry F, et al. CA153: a prognostic marker in breast cancer [J]. Int J Biol Markers, 2000, 15(4): 330333.
4.	Jnicke F, Prechtl A, Thomssen C, et al; German N0 Study Group. Randomized adjuvant chemotherapy trial in highrisk, lymph nodenegative breast cancer patients identified by urokinasetype plasminogen activator and plasminogen activator inhibitor type 1 [J]. J Natl Cancer Inst, 2001, 93(12): 913920.
5.	李亚芬. 乳腺癌肿瘤标志物的研究和临床应用进展 [J]. 中国普外基础与临床杂志, 2002, 9(5): 298299.
6.	Xu Y, Kimura N, Yoshida R, et al. Immunohistochemical study of Muc1, Muc2 and human gastric mucin in breast carcinoma: relationship with prognostic factors [J]. Oncol Rep, 2001, 8(5): 11771182.
7.	Dupont WD, Parl FF, Hartmann WH, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia [J]. Cancer, 1993, 71(4): 12581265.
8.	Ford HL, Kabingu EN, Bump EA, et al. Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: A possible mechanism of breast carcinogenesis [J].Proc Natl Acad Sci U S A, 2004, 95(21): 1260812613.
9.	Wang L, Shao ZM. Cyclin E expression and prognosis in breast cancer patients: a metaanalysis of published studies [J]. Cancer Invest, 2006, 24(6): 581587.
10.	刘扬清, 郑云会. 血清CA153检测对复发性乳腺癌的临床价值 [J]. 中国肿瘤临床与康复, 2003, 10(6): 492494.
11.	徐凤英, 田小平. CA125和SIL2R联检在诊断卵巢癌中应用价值 [J]. 放射免疫学杂志, 2001, 14(5): 272273.
12.	苗晓, 周勤. 血清CA125在卵巢良恶性肿瘤诊断及监控的临床分析 [J]. 中外医疗, 2008, 27(31): 139140.
13.	杨钟莉, 李辉, 张辉. 血清CA125、CEA、AFP联检对卵巢肿瘤的诊断价值 [J]. 山东医药, 2004, 44(27): 1314.
14.	陈光意, 苏金明, 吕晓娴. CEA、CA153及CA125对乳腺癌的诊断 [J]. 中国误诊学杂志, 2005, 5(5): 871872.
15.	陈建伟, 宋建国. CA153, CEA及CA125联合检测对乳腺癌诊断的意义 [J]. 上海医学检验杂志, 2000, 15(4): 256.
16.	陈文思, 丁莲, 王潭枫. 联合检测血清CA153、CA125、CA199对乳腺癌的临床意义 [J]. 热带医学杂志, 2007, 7(9): 879881.
17.	Yang XR, Pfeiffer RM, GarciaClosas M, et al. Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a populationbased study [J]. Cancer Res, 2007, 6(21): 1060810617.
18.	段秋林, 李扬威, 石峰, 等. 联合检测胃液中CEA、CA199、CA242在胃癌诊断中的应用价值 [J]. 肿瘤防治研究, 2007, 34(8): 607609.
19.	张铭娜, 徐娟, 高燕, 等. 血清CA199在上皮性卵巢癌中的临床意义 [J]. 天津医药, 2009, 37(3): 186188.

1. 张喜庆, 王珠, 乔新民. 乳腺癌的现状和远景 [J]. 中华外科杂志, 2002, 40(3): 161163.
2. Haglund C, Lundin J, Kuusela P, et al. CA242, a new tumour marker for pancreatic cancer: a comparison with CA199, CA50 and CEA [J]. Br J Cancer, 1994, 70(3): 487492.
3. Duffy MJ, Shering S, Sherry F, et al. CA153: a prognostic marker in breast cancer [J]. Int J Biol Markers, 2000, 15(4): 330333.
4. Jnicke F, Prechtl A, Thomssen C, et al; German N0 Study Group. Randomized adjuvant chemotherapy trial in highrisk, lymph nodenegative breast cancer patients identified by urokinasetype plasminogen activator and plasminogen activator inhibitor type 1 [J]. J Natl Cancer Inst, 2001, 93(12): 913920.
5. 李亚芬. 乳腺癌肿瘤标志物的研究和临床应用进展 [J]. 中国普外基础与临床杂志, 2002, 9(5): 298299.
6. Xu Y, Kimura N, Yoshida R, et al. Immunohistochemical study of Muc1, Muc2 and human gastric mucin in breast carcinoma: relationship with prognostic factors [J]. Oncol Rep, 2001, 8(5): 11771182.
7. Dupont WD, Parl FF, Hartmann WH, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia [J]. Cancer, 1993, 71(4): 12581265.
8. Ford HL, Kabingu EN, Bump EA, et al. Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: A possible mechanism of breast carcinogenesis [J].Proc Natl Acad Sci U S A, 2004, 95(21): 1260812613.
9. Wang L, Shao ZM. Cyclin E expression and prognosis in breast cancer patients: a metaanalysis of published studies [J]. Cancer Invest, 2006, 24(6): 581587.
10. 刘扬清, 郑云会. 血清CA153检测对复发性乳腺癌的临床价值 [J]. 中国肿瘤临床与康复, 2003, 10(6): 492494.
11. 徐凤英, 田小平. CA125和SIL2R联检在诊断卵巢癌中应用价值 [J]. 放射免疫学杂志, 2001, 14(5): 272273.
12. 苗晓, 周勤. 血清CA125在卵巢良恶性肿瘤诊断及监控的临床分析 [J]. 中外医疗, 2008, 27(31): 139140.
13. 杨钟莉, 李辉, 张辉. 血清CA125、CEA、AFP联检对卵巢肿瘤的诊断价值 [J]. 山东医药, 2004, 44(27): 1314.
14. 陈光意, 苏金明, 吕晓娴. CEA、CA153及CA125对乳腺癌的诊断 [J]. 中国误诊学杂志, 2005, 5(5): 871872.
15. 陈建伟, 宋建国. CA153, CEA及CA125联合检测对乳腺癌诊断的意义 [J]. 上海医学检验杂志, 2000, 15(4): 256.
16. 陈文思, 丁莲, 王潭枫. 联合检测血清CA153、CA125、CA199对乳腺癌的临床意义 [J]. 热带医学杂志, 2007, 7(9): 879881.
17. Yang XR, Pfeiffer RM, GarciaClosas M, et al. Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a populationbased study [J]. Cancer Res, 2007, 6(21): 1060810617.
18. 段秋林, 李扬威, 石峰, 等. 联合检测胃液中CEA、CA199、CA242在胃癌诊断中的应用价值 [J]. 肿瘤防治研究, 2007, 34(8): 607609.
19. 张铭娜, 徐娟, 高燕, 等. 血清CA199在上皮性卵巢癌中的临床意义 [J]. 天津医药, 2009, 37(3): 186188.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Significance of Detection of CA153, CA125, and CA19-9 in Diagnosis of Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content